Abbreviations
|
Full name
|
2-AG |
2-arachidonoylglycerol |
5-HT1A
|
serotonin receptor 1A |
AEA |
anandamide |
Aβ |
amyloid beta |
CB1 |
cannabinoid receptor type 1 |
CB2 |
cannabinoid receptor type 2 |
CBC |
cannabichromene |
CBCA |
canabichromenic acid |
CBD |
cannabidio |
CBDA |
cannabidiolic acid |
CBG |
Cannabigerol |
CBGA |
Cannabigerolic acid |
CBN |
Cannabinol |
CBNA |
Cannabinolic acid |
COX-1 |
Cyclooxygenase-1 |
COX-2 |
Cyclooxygenase-2 |
Δ-9-THC |
Delta-9-tetrahydrocannabinol |
DAGL |
diacylglycerol lipase |
DS |
Dravet Syndrome |
ECS |
Endocannabinoid system |
ECs |
Endocannabinoids |
EMA |
European Medicines Agency |
ER |
endoplasmic reticulum |
EU |
European Union |
FAAH |
Fatty acid amide hydrolase |
FDA |
Food and Drug Administration |
GPP |
Geranyl diphosphate |
HDF |
Human dermal fibroblasts |
HDL |
High-density lipoprotein |
HRPC |
Hormone-refractory prostate cancer |
IBD |
Inflammatory bowel disease |
iNOS |
Nitric oxide synthase |
IOP |
Intraocular pressure |
LGS |
Lennox Gastaut Syndrome |
MCD |
Methionine/choline-deficient |
MDSCs |
Monocytic-myeloid-derived suppressor cells |
MGL |
Monoacylglycerol lipase |
MRSA |
Methicillin-resistant strains |
MS |
Multiple sclerosis |
NASH |
Non-alcoholic steatohepatitis |
PPAR |
Peroxisome proliferator-activated receptor |
ROS |
Reactive oxygen species |
SOD-1 |
Superoxide dismutase-1 |
THC |
Tetrahydrocannabinol |
THCA |
Tetrahydrocannabinolic acid |
TME |
Tumor microenvironment |
Tregs |
T-regulatory cells |
TRPM8 |
transient receptor potential cation channel 8 |
TRPM8 |
TRP melastatin type 8 |
TRPV |
transient receptor potential vanilloid |
TSC |
Tuberous Sclerosis Complex |
α2AR |
α2-adrenoceptor |
2-AG |
2-arachidonoylglycerol |